Corcept Therapeutics (NASDAQ:CORT) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.
CORT has been the subject of several other research reports. Stifel Nicolaus started coverage on Corcept Therapeutics in a report on Thursday, August 31st. They issued a “buy” rating and a $20.00 price target for the company. Zacks Investment Research downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, Piper Jaffray Companies set a $18.00 price target on Corcept Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. Corcept Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $18.20.
Corcept Therapeutics (NASDAQ:CORT) opened at $16.21 on Thursday. Corcept Therapeutics has a 52 week low of $6.70 and a 52 week high of $20.77. The stock has a market capitalization of $1,903.59, a PE ratio of 57.52 and a beta of 1.89.
In other Corcept Therapeutics news, Director G Leonard Baker, Jr. sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $17.59, for a total value of $527,700.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 19.20% of the company’s stock.
Several institutional investors have recently bought and sold shares of CORT. GSA Capital Partners LLP increased its position in shares of Corcept Therapeutics by 57.8% during the third quarter. GSA Capital Partners LLP now owns 151,282 shares of the biotechnology company’s stock worth $2,920,000 after purchasing an additional 55,400 shares in the last quarter. California Public Employees Retirement System increased its position in shares of Corcept Therapeutics by 9.6% during the third quarter. California Public Employees Retirement System now owns 162,459 shares of the biotechnology company’s stock worth $3,135,000 after purchasing an additional 14,259 shares in the last quarter. Caxton Associates LP purchased a new stake in shares of Corcept Therapeutics during the third quarter worth approximately $199,000. Jane Street Group LLC purchased a new stake in shares of Corcept Therapeutics during the third quarter worth approximately $928,000. Finally, Cornerstone Capital Management Holdings LLC. increased its position in shares of Corcept Therapeutics by 268.4% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 105,000 shares of the biotechnology company’s stock worth $2,025,000 after purchasing an additional 76,500 shares in the last quarter. Institutional investors and hedge funds own 64.71% of the company’s stock.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.